The Effect of Covid-19 mRNA Vaccine on Serum Anti-Mullerian Hormone Levels

Introduction:The Covid-19 pandemic exerted tremendous pressure on scientists to develop safe and effective vaccines. A few delivery systems for next generation vaccines against Covid-19 were introduced a year ago. Aim: The aim of the present study was to evaluate any potential association between SARS-CoV-2 mRNA vaccine to future fertility expressed by the ovarian reserve.

Materials and methods:We included reproductive aged women (18–42 years) and adolescent girls aged 12-16 that were vaccinated by two Pfizer-BioNTech Covid-19 vaccines (21 days apart). Blood samples were collected for AMH levels before the first mRNA vaccine administration and additional blood samples for AMH levels were collected after 3 months. Primary outcome was defined as the absolute and percentage change in AMH levels.

Results: The study group consisted of 129 women and 22 adolescent girls who received two mRNA vaccinations. The Mean AMH levels were 4.9 ± 4.1 g/L and 4.8± 4.4 g/L at baseline and after 3 months, respectively (P = 0.1).

To account for possible age-specific changes of AMH, sub-analyses were performed for the 2 groups (adolescent girls and women aged 18-42 years). No significant differences for the changes in AMH levels before and after vaccinations (Delta AMH) were observed for the two groups age groups ( p=0.1, p=0.2).

We conclude that Ovarian reserve as assessed by serum AMH levels is not altered at 3 months following mRNA SARS-CoV-2 vaccination